<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-116570</identifier>
<setSpec>1695-4033</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Risk assessment of thrombotic events after the use of activated factor VII</dc:title>
<dc:description xml:lang="en">Introduction: The objective of this study was to analyze the incidence of thrombotic complications related to recombinant human factor VII a (rFVIIa) therapy for severe postoperative bleeding in cardiac surgery. Material and methods: A retrospective matched case-control study was conducted over two years, including 72 children admitted to intensive care unit and treated with rFVIIa because of a severe bleeding during or after cardiac surgery. A control group of 63 patients was chosen, who were statistically comparable in sex, weight, diagnosis, surgical risk according RASCH-1 score, and surgical characteristics, was chosen. Results: There were no significant differences between cases and controls either in the rate of thrombosis (20% vs 28%, P=0.540), or in the mortality rate (16% vs 9.5%, P=0.208). Conclusions: In our study, the rFVIIa therapy was shown to be useful in controlling severe operative bleeding in pediatric cardiac surgery, but does not seem to increase the risk of thrombotic complications or mortality rate in the postoperative period (AU)</dc:description>
<dc:creator>Martínez López, M. C</dc:creator>
<dc:creator>Martínez López, A. B</dc:creator>
<dc:creator>Ramos Navarro, C</dc:creator>
<dc:creator>Alcaraz Romero, A. J</dc:creator>
<dc:creator>Fernández-Llamazares, C. M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción: El objetivo del estudio fue analizar la incidencia de efectos trombóticos relacionada con la administración de factor VII humano recombinante activo (rFVIIa) en el tratamiento de la hemorragia grave tras la cirugía cardiaca. Material y métodos: Estudio retrospectivo de casos-controles pareado, de 2 años de duración, que incluyó a 72 niños ingresados en cuidados intensivos y tratados con rFVIIa por una hemorragia grave, durante o tras la cirugía cardiaca. Utilizamos un grupo control de 63 pacientes, estadísticamente comparables en cuanto a sexo, peso, diagnóstico, riesgo quirúrgico según la clasificación RACHS-1 y las características quirúrgicas. Resultados: No existieron diferencias significativas en la incidencia de fenómenos trombóticos (20% en casos y 28% en controles, p = 0,540), ni en la mortalidad (16% en casos y 9,5% controles, p = 0,208). Conclusión: En nuestra serie, el tratamiento con rFVIIa ha demostrado ser útil en el control de la hemorragia incoercible en niños sometidos a cirugía cardiaca, y no parece aumentar el riesgo de fenómenos trombóticos ni la mortalidad en el periodo postoperatorio (AU)</dc:description>
<dc:source>An Pediatr (Barc);79(3): 177-181, sept. 2013. ilus, tab</dc:source>
<dc:identifier>ibc-116570</dc:identifier>
<dc:title xml:lang="es">Evaluación del riesgo de fenómenos trombóticos tras el uso de factor VII activado</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d7399</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d29315</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d32645^s22057</dc:subject>
<dc:subject>^d2694</dc:subject>
<dc:subject>^d6500</dc:subject>
<dc:subject>^d24643^s22020</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d24551</dc:subject>
<dc:subject>^d2715</dc:subject>
<dc:subject>^d1818^s22036</dc:subject>
<dc:subject>^d14312^s22036</dc:subject>
<dc:type>article</dc:type>
<dc:date>201309</dc:date>
</metadata>
</record>
</ibecs-document>
